Storys zum Thema Medizinische Behandlung

Dr. Reddy's Laboratories SA

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment

InSightec

European Parliament Recognizes Essential Tremor as Official Disease in Ground-Breaking Declaration

Brussels (ots/PRNewswire) - The Insightec-organized conference resulted in a Joint Declaration, promising new hope for patients suffering from the condition The European Parliament, in collaboration with Insightec and patient advocacy groups, has taken a historic step forward in the healthcare realm by signing a ...

Isotopia Molecular Imaging

Isotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, has received marketing authorization in the Netherlands (RVG 130527)

Petach Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, our PSMA -11 kit, has received marketing authorization in the Netherlands (RVG 130527). This landmark approval marks a significant milestone in our ongoing commitment to improve healthcare and patient ...

Norgine B.V

Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia

Amsterdam (ots/PRNewswire) - Norgine B.V. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia. The ...

ARTCLINE GmbH

ARTCLINE successfully completes capital increases of EUR 4.4 million

Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...

Norgine

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...

FDX Fluid Dynamix GmbH

4

FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX

Pulsenmore Ltd.

Pulsenmore is expanding the application of its home ultrasound solution for pregnant women: a clinical trial with Michigan Medicine will focus on the remote assessment of the fetal biophysical profile

Ramat Gan, Israel (ots/PRNewswire) - Pulsenmore (TASE:PULS), the world leader in self-scan ultrasound technology for at-home use and remote clinical diagnosis, announces its new clinical study collaboration with Michigan Medicine. The study will examine the ability to conduct a remote biophysical profile (BPP) test, ...

Epitomee Medical

Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance

Caesarea, Israel (ots/PRNewswire) - Epitomee® (TASE: EPIT) announced today that on February 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in the USA, reaching a significant milestone in the company's journey. The Epitomee® capsule offers an innovative, orally administered, drug free, and clinically proven as effective and safe solution, for ...

Phagenesis

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Manchester, England (ots/PRNewswire) - Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round. The combined European and United States investment syndicate was led by EQT Life ...

InSightec

Insightec's Groundbreaking Transcranial MR-Guided Focused Ultrasound (MRgFUS) Approved for Additional Reimbursement for Essential Tremor in Germany

Berlin (ots/PRNewswire) - Germany is latest – and largest – European country to enable substantial access to focused ultrasound, offering new hope of relief for those suffering with movement disorders Insightec, a pioneer and global leader in focused ultrasound, is pleased to announce that its transcranial ...

Johnson & Johnson Biosense Webster

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

Irvine, Calif. (ots/PRNewswire) - - Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. - Integrated with the world's leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ...

RHEACELL GmbH und Co. KG

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Helmholtz Zentrum München

Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target

Koehler Group

Extension of Wastewater Treatment Plant at Koehler Paper in Kehl

Leipzig Tourismus und Marketing GmbH

5

Pioneering Heart Surgery and Medical Congresses in Leipzig

Helmholtz Zentrum München

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial

Helmholtz Zentrum München

What Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications

Acousia Therapeutics GmbH

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...

ARTTIC Innovation GmbH

2

OPTIMA cancer project announces the Region Uppsala as new partner

Acousia Therapeutics GmbH

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...

Helmholtz Zentrum München

New Source of Stem Cells in Injury-Affected Brains of Patients

Takeda Pharma Vertrieb GmbH & Co. KG

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...

Grünenthal Group

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...